Union Korea Pharm Co., Ltd. (KOSDAQ:080720)
South Korea · Delayed Price · Currency is KRW 2,725.00
-310.00 (-10.21%)
At close: Oct 11, 2024
Union Korea Pharm Income Statement
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Revenue | 36,378 | 51,280 | 63,169 | 61,293 | 48,304 |
Other Revenue | -0 | - | -0 | - | - |
| 36,378 | 51,280 | 63,169 | 61,293 | 48,304 | |
Revenue Growth (YoY) | -29.06% | -18.82% | 3.06% | 26.89% | -4.12% |
Cost of Revenue | 28,619 | 37,156 | 42,388 | 37,377 | 33,154 |
Gross Profit | 7,759 | 14,124 | 20,781 | 23,917 | 15,150 |
Selling, General & Admin | 15,801 | 27,632 | 24,675 | 22,147 | 23,987 |
Research & Development | 812.4 | 1,027 | 833.33 | 922.15 | 2,451 |
Amortization of Goodwill & Intangibles | 55 | 301.46 | 311.24 | 350.72 | 368.82 |
Other Operating Expenses | 232.79 | 264.02 | 244.29 | 294.22 | 196.45 |
Operating Expenses | 31,085 | 32,778 | 35,463 | 22,646 | 25,764 |
Operating Income | -23,326 | -18,654 | -14,682 | 1,271 | -10,615 |
Interest Expense | -3,243 | -3,920 | -4,112 | -2,843 | -2,229 |
Interest & Investment Income | 27.29 | 97.74 | 105.43 | 47.61 | 46.64 |
Earnings From Equity Investments | -518.08 | -23.89 | -19.46 | -5.47 | -9.49 |
Currency Exchange Gain (Loss) | -24.04 | 89.97 | 9.98 | -55.14 | 96.43 |
Other Non Operating Income (Expenses) | -259.36 | 7,264 | 1,695 | 2,528 | -1,628 |
EBT Excluding Unusual Items | -27,343 | -15,146 | -17,004 | 943.54 | -14,338 |
Gain (Loss) on Sale of Assets | 35.25 | 0.67 | 129.04 | - | 7.54 |
Asset Writedown | - | - | - | - | -146.73 |
Other Unusual Items | -498.94 | -3,826 | 2,471 | - | - |
Pretax Income | -27,806 | -18,972 | -14,404 | 943.54 | -14,477 |
Income Tax Expense | 3,014 | 1,944 | 3,753 | 1,876 | -3,367 |
Net Income | -30,820 | -20,916 | -18,156 | -932.02 | -11,109 |
Net Income to Common | -30,820 | -20,916 | -18,156 | -932.02 | -11,109 |
Shares Outstanding (Basic) | 7 | 7 | 7 | 7 | 8 |
Shares Outstanding (Diluted) | 7 | 7 | 7 | 7 | 8 |
Shares Change (YoY) | 0.03% | 0.09% | -2.14% | -5.05% | 16.95% |
EPS (Basic) | -4263.00 | -2894.00 | -2514.45 | -126.31 | -1429.59 |
EPS (Diluted) | -4263.00 | -2894.00 | -2514.45 | -126.31 | -1430.00 |
Free Cash Flow | -1,230 | -529.23 | -901.15 | -8,429 | -5,254 |
Free Cash Flow Per Share | -170.11 | -73.22 | -124.80 | -1142.33 | -676.09 |
Gross Margin | 21.33% | 27.54% | 32.90% | 39.02% | 31.36% |
Operating Margin | -64.12% | -36.38% | -23.24% | 2.07% | -21.98% |
Profit Margin | -84.72% | -40.79% | -28.74% | -1.52% | -23.00% |
Free Cash Flow Margin | -3.38% | -1.03% | -1.43% | -13.75% | -10.88% |
EBITDA | -21,523 | -15,777 | -10,792 | 5,266 | -6,389 |
EBITDA Margin | -59.16% | -30.77% | -17.08% | 8.59% | -13.23% |
D&A For EBITDA | 1,803 | 2,877 | 3,890 | 3,994 | 4,226 |
EBIT | -23,326 | -18,654 | -14,682 | 1,271 | -10,615 |
EBIT Margin | -64.12% | -36.38% | -23.24% | 2.07% | -21.98% |
Effective Tax Rate | - | - | - | 198.78% | - |
Advertising Expenses | 5.29 | 302.81 | 1,984 | 865.84 | 1,090 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.